Antibiotic Prophylaxis in Rhinoplasty

Summary

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Conditions

• Nasal Obstruction
• Nasal Surgical Procedures

Interventions

DRUG

Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.

Treatment Arm A

DRUG

Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days

Treatment Arm B

Sponsors & Collaborators

• Washington University School of Medicine

  collaborator OTHER

• Vanderbilt University School of Medicine

  collaborator OTHER

• University of Washington

  collaborator OTHER

• Duke University

  collaborator OTHER

• Harvard University

  collaborator OTHER

• University of Kansas Medical Center

  collaborator OTHER

• University of Cincinnati

  collaborator OTHER

• Loma Linda University

  collaborator OTHER

• Stanford University

  lead OTHER

Principal Investigators

• Sam P Most, MD · Stanford Facial Plastic and Reconstructive Surgery

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-20

Primary Completion

2026-12-20

Completion

2027-04-20

FDA Drug

Yes

Countries

• United States

Study Locations